| Identification | Back Directory | [Name]
N106 | [CAS]
862974-25-2 | [Synonyms]
4-Methoxy-N-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl-2-benzothiazolamine
N-(4-Methoxybenzo[d]thiazol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine | [Molecular Formula]
C17H14N4O3S | [MDL Number]
MFCD05892638 | [MOL File]
862974-25-2.mol | [Molecular Weight]
354.38 |
| Chemical Properties | Back Directory | [Boiling point ]
545.4±56.0 °C(Predicted) | [density ]
1.390±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 20 mg/ml | [form ]
A solid | [pka]
1.03±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
N106 is an activator of SUMO-activating enzyme, E1 ligase. | [in vivo]
In a murine model, the half-life of N106 is determined to be ～65.4?min with a Cmax of ～2.24?μM when the mice received 10?mg/kg of N106 by intravenous injection. The oral bioavailability (F%) is 56% and 50%, and terminal elimination half-life (t1/2) is 19?min[1].
?
In vivo, N106 (10 mg/kg) increases cardiac SERCA2A SUMOylation, and significantly improves ventricular function in mice with heart failure[1]. |
|
|